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Introduction. The nuclear factor-kappaB (NF-κB) has been shown to upregulate pro-apoptotic 
mediators such as TRAIL-DR4/-DR5 receptors and the p53 transcription factor depending on the 
type of stimulus and the cell type involved. Previously, apple procyanidins (Pcy) have been shown to 
upregulate the expression of TRAIL-DR4/-DR5 and thereby overcoming the resistance of human colon 
cancer-derived metastatic SW620 cells to TRAIL.
Objectives. NF-κB and p53 were investigated for their involvement in the Pcy-triggered apoptosis of 
human derived-metastatic colon cancer (SW620) cells.
Materials and methods. Cell death, p53, TRAIL-DR4/-DR5 proteins were analyzed by flow cytometry. 
DR4/DR5 mRNA was analyzed by RT-PCR in real time. Activated p50/p65 and p53 forms were studied 
by ELISA and immunoblotting.
Results. Pcy-triggered cell death was prevented by specific inhibitors of NF-κB and of p53: amino-
4-(4-phenoxy-phenylethylamino) quinazoline (QNZ) and pifithrin α (Pα), respectively. QNZ and Pα 
inhibited the Pcy-dependent activation of TRAIL-DR4/-DR5 death receptors. However, the upregulation 
of TRAIL-DR4 by Pcy was  significantly decreased only when NF-κB and p53 inhibitors were used in 
combination; this effect was not observed with a single inhibitor. This effect was not observed for TRAIL-
DR5 and suggested that the expression of each TRAIL-death receptor may be regulated differently.
Conclusions. These data suggested that NF-κB and p53 are partially required in Pcy-triggered 
apoptosis of SW620 cells by up-regulating the expression of TRAIL-DR4/-DR5. In addition, the ratio 
between TRAIL-DR4/-DR5 may be a determining factor in the activation of TRAIL-death receptor 
mediated apoptosis.
Key words: Apoptosis, colorectal neoplasms, flavonoids, tumor suppressor protein p53; receptors, 
TNF-related apoptosis-inducing ligand.
Implicación de NF-κB y p53 en la expresión de receptores de muerte-TRAIL y apoptosis por 
procianidinas en células metastásicas humanas SW620
Introducción. Se ha demostrado que el factor nuclear-κB y p53 aumentan los mediadores 
proapoptósicos como los receptores de muerte TRAIL-DR4/-DR5, según el estímulo y el tipo celular. 
Previamente demostramos que las procianidinas de manzana aumentaban la expresión de TRAIL-
DR4/-DR5, superando la resistencia a TRAIL característica en células humanas metastásicas SW620 
derivadas del cáncer de colon.
Objetivo. Investigar si NF-κB y p53 están involucrados en la apoptosis inducida por procianidinas en 
las células SW620.
Materiales y métodos. La muerte celular y las proteínas p53, TRAIL-DR4/-DR5 se analizaron por 
citometría de flujo. Los ARN mensajeros (ARNm) de DR4/DR5 se analizaron por RT-PCR. Las formas 
activadas de p50/p65 y p53 se estudiaron por ELISA e inmunodetección.
Resultados. La muerte celular activada por procianidinas fue prevenida por inhibidores específicos 
de NF-κB y de p53: amino-4-(4-fenoxi-feniletilamino)-quinazolina y pifitrina α, respectivamente. La 
quinazolina y la pifitrina α inhibieron la activación dependiente de procianidinas de TRAIL-DR4/DR5. 
Sin embargo, el aumento en la expresión de TRAIL-DR4 disminuyó significativamente sólo cuando la 
quinazolina y la pifitrina α se usaron simultáneamente; este efecto no se observó con cada uno por 
separado. No se observaron para TRAIL-DR5 estos efectos, lo cual sugiere que la expresión de cada 
receptor de muerte TRAIL puede estar regulada en forma diferente.
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Conclusiones. Estos datos sugieren que NF-κB y p53 se requieren parcialmente en la apoptosis de 
células SW620 inducida por procianidinas mediante el aumento en TRAIL-DR4/-DR5. La proporción 
de DR4/DR5 podría ser un factor determinante en la activación de la apoptosis por vía de TRAIL-DR4/-
DR5. 
Palabras clave: apoptosis, neoplasias colorrectales, flavonoides, proteína p53 supresora de tumor, 
receptores del ligando inductor de apoptosis relacionado con el FNT 
The nuclear factor kappa beta (NF-κB) is a 
transcription factor that plays an important role 
in tumor formation and progression by regulating 
the transcription of genes that promote cell 
proliferation, survival, inflammation, invasion (1), 
as well as apoptosis (2,3). The NF-κB is composed 
of homo- and heterodimeric complexes of 
members of the NF-κB family. Five subunits occur 
in mammals: p50, p65, c-Rel, p52, RelB. These 
proteins share a 300-amino acid sequence in the 
N-terminal region known as the Rel homology 
and mediate DNA-binding, protein dimerization, 
and nuclear localization. The p50/p65 is the most 
common heterodimer found in the NF-κB signaling 
pathway. NF-κB exists in an inactive form in the 
cytoplasm, bound to the inhibitory IκB proteins. 
Treatment of cells with various inducers results in 
the phosphorylation, ubiquitination and subsequent 
degradation of IκB proteins favouring the formation 
of NF-κB dimers, which subsequently translocate 
to the nucleus, where they activate appropriate 
target genes (4).
In a number of systems, NF-κB has a demonstrable 
anti-apoptotic function (5). NF-κB inhibited TNF-
mediated apoptosis in Jurkat T cells, primary 
rat and human fibroblasts, and in MCF-7 breast 
carcinoma cell lines (5-7). NF-κB also protect 
against chemotherapy-mediated apoptosis in 
a number of malignant cell lines (8). In contrast, 
convincing evidence has highlighted a paradoxical 
pro-apoptotic role for NF-κB (2,3,9-12). These 
observations raise the possibility that sites in 
pro- or anti-apoptotic genes may exhibit different 
preferences for particular subunits of the NF-κB 
dimer, and that NF-κB may have signal-specific 
effects on cell survival. NF-κB has been implicated 
in the up-regulation of pro-apoptotic genes such 
as Bax (13), Fas, FasL (14), and TRAILDR4/-DR5 
(15,16) genes. NF-κB activation may also cooperate 
with p53 to induce apoptosis (9,17) by the up-
regulation of these genes by p53 (18,19). However, 
the regulation of NF-κB transcriptional activity that 
leads to the up-regulation of pro-apoptotic genes 
is unclear.
The p53 protein is a transcription factor that can 
act as a tumor suppressor and can be induced 
by DNA damage, whereas in unstressed cells, 
p53 levels remain low. The p53 protein plays a 
key role in cell cycle arrest and in the induction of 
apoptosis (20,21). Tumor suppressor protein p53 
also up-regulates the expression of TRAIL-death 
receptors DR4 and DR5, since p53-binding sites 
have been found in the genomic locus of DR4 and 
DR5 (19,21,22). TRAIL-death receptors can induce 
an apoptotic signal after binding with their specific 
ligand TRAIL in a wide variety of tumor cell lines, 
but normal cells are relatively resistant to TRAIL 
(23).
Apple products have been tested in experimental 
animal models to treat chemically or genetically-
induced tumors of the colon.  They have provided 
a first indication of cancer chemopreventive 
efficacy in vivo which is attributed in great part 
to flavonoids (24-29). Apples are an important 
source of flavonoids, one of the main polyphenols 
present in human diet.  Flavanols represent the 
major subclass of flavonoids containing monomers 
(epicatechin and catechin) and polymeric forms 
(procyanidins, Pcy). The Pcy are oligomeric and 
polymeric polyphenols formed by the association of 
several monomeric units of flavan-3-ols (catechin 
and epicatechin) (30,31). The regular consumption 
of Pcy-containing foods has been associated with 
a reduced risk of various types of cancers (32). 
Flavonoids are able to increase the expression 
of pro-apoptotic mediators and prevent or delay 
tumor development.  In this regard, the induction 
of apoptosis appears as one of the most important 
targets in a chemopreventive approach (33).
In previous studies, we reported that apple Pcy 
triggered apoptosis in human colon carcinoma-
derived metastatic TRAIL-resistant SW620 
cells through the activation of TRAIL-DR4/DR5 
receptors (34,35). Therefore, since NF-κB and p53 
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have binding sites in TRAIL-DR4/-DR5 promoter 
regions, the current investigation was directed to 
determining whether NF-κB and p53 are involved 
in Pcy-triggered apoptosis.
Materials and methods
Isolation and characterization of apple 
procyanidins
Polyphenols were purified from a cider apple 
(Malus domestica, variety Antoinette) as reported 
by Souquet et al. (36). In brief, apples were reduced 
to a homogeneous powder which was extracted 
by water:ethanol:acetic acid (975:1000:25). After 
filtration, evaporation under vacuum and freeze 
drying, the crude extract was dissolved in 2.5% 
acetic acid and separated by preparative HPLC 
(Lichrospher RP 18, 12 µm, Merck, Darmstadt, 
Germany) to remove sugars and other non-phenolic 
polar compounds. Polyphenols were eluted 
with a acetonitrile:water:acetic acid (300:700:25) 
solution. Fractions containing polyphenols were 
evaporated and freeze-dried. The polyphenols 
were fractionated on a Fractogel column (36,37). 
Pcy were characterized and quantified by reverse-
phase HPLC after thioacidolysis. On a weight basis, 
the Pcy-fraction contained 70% Pcy, consisting 
of 95% (-)- epicatechin and 4% (+)-catechin. 
The mean degree of polymerization approached 
seven. The Pcy fraction was almost totally devoid 
of monomeric catechins and other phenols (<2%). 
Pcy was diluted in dimethylsulfoxide (DMSO) and 
used at 80 µg/ml final concentration.
Cell culture and treatments
SW620 cells were obtained from the European 
Collection of Animal Cell Culture (ECACC, Salisbury, 
UK). They were cultured in 75 cm2 Falcon flasks 
in Dulbecco’s modified Eagle’s medium containing 
25 mM glucose, 2 mM L-glutamine, 10% heat-
inactivated (56°C) horse serum, 100 U/ml penicillin, 
100 µg/ml streptomycin and 1% non-essential amino 
acids (Invitrogen Corp., Cergy Pontoise, France). 
Incubations were carried out at 37°C in a humidified 
atmosphere with 5% CO2. The culture medium was 
replaced every 48 h. For all experiments, horse 
serum was reduced to 3%, and the medium was 
supplemented with 5 µg/ml transferrin, 5 ng/ml 
selenium and 10 µg/ml insulin (ITS-defined medium; 
Gibco, Invitrogen, Cergy-Pontoise, France). Cells 
were exposed to the different compounds 24 h after 
seeding and incubated for 24 or 48 h. The DMSO 
final concentration in culture medium was 0.1% 
for control and treated cells. The stock solution of 
pifithrin α (Pα) (Calbiochem, Nottingham, United 
Kingdom), an inhibitor of the transcriptional activity 
of p53, was diluted in DMSO and tested at 30 
µM. The 6-amino-4-(4-phenoxyphenylethylamino) 
quinazoline (QNZ) (Calbiochem, Nottingham, 
United Kingdom), an inhibitor of the transcriptional 
activation of nuclear factor-kappa B, was diluted in 
DMSO and tested at 30 nM. Cells were pretreated 
for 30 min with Pα with and without QNZ before 
addition of Pcy to culture medium.
Flow cytometric analysis of sub G0/G1 cell 
population
The amount of dying and dead cells of the cell 
populations was determined by flow cytometry 
analysis and corresponded to the percentage of 
hypodiploid cells present in the sub-G0/G1 region 
as shown previously (28,32). Cells were seeded 
in culture dishes (1x106 cells per 10 cm internal 
diameter or 2x105 cells per 2.5 cm internal diameter) 
and treated with DMSO 0.1% (control) or Pcy (80 
µg/ml) with or without QNZ (30 nM) and Pα (30 µM) 
for 24 h or 48 h. Cells were pretreated for 30 min 
with Pα with or without QNZ before addition of Pcy 
or DMSO to culture medium. Control and treated 
cells were harvested by trypsinization, centrifuged 
and washed twice with ice-cold PBS 0.1 M, pH 7.2 
at 1,800 X g for 5 min at 4°C, and fixed in 1 ml 
methanol:PBS (9:1, v/v) at -20°C for at least 30 
min. The fixed cells were washed twice with ice-
cold PBS and cell pellets were resuspended in 
100 µl PBS containing 0.25 mg/ml RNAse A and 
0.1 mg/ml propidium iodide (PI) (Sigma-Aldrich, 
Munich, Germany), incubated in darkness at 
37°C for 30 min. Cell cycle phase distribution was 
analyzed using a FACScan flow cytometer (Beckton 
Dickinson Immunocytometry Systems, San Jose, 
CA, USA). Data from 10,000 events per sample 
were collected and analyzed using the CellQuest 
software. Apoptosis was quantitatively measured 
as the percentage of hypodiploid cells in the sub-
G0/G1 region using the Cell Fit analysis program 
(Beckton Dickinson, USA).
Measure of activated p50/p65 subunits of NF-
kB
Cells were harvested by scraping, washed twice in 
PBS and stored at -20°C. NF-κB release activation 
was quantified with the TransAM NF-κB Family 
Transcription Factor Assay Kit (Active Motif Europe, 
Rixensart, Belgium) in a 96-well plate according to 
the manufacturer’s instructions. This system is an 
ELISA method for detecting active form of NF-κB 
contained in nuclear extract; NF-κB specifically 
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binds to an immobilized oligonucleotide in the 
ELISA plate that contains the NF-κB consensus 
site (5’-GGGACTTTCC-3’). The Raji nuclear 
extract was provided as positive control. Nuclear 
extracts were prepared using the Nuclear Extract 
Kit (Active Motif Europe, Rixensart, Belgium). The 
nuclear extracts of SW620 cells were incubated 
overnight, followed by addition of primary antibodies 
specifically used to detect an epitope on p50 and 
p65–epitopes accessible only when NF-κB is 
activated and bound to its target DNA. Horseradish 
peroxidase-conjugated Streptavidin was then used 
for colorimetric detection and assessed by reading 
absorbance at 450 nm. Values were expressed as 
optical density (OD).
Flow cytometric analysis of intracellular p53 
expression
Cells (1x106) were seeded and treated as 
described for the sub-G0/G1 cell population. Cells 
were harvested by trypsinization, washed twice 
with ice cold PBS with 2% BSA and fixed with 4% 
paraformaldehyde for 30 min at 4°C. Cells were 
permeabilized by twice treating the cell pellet with 
200 µl of wash buffer containing 0.5% Tween-
20 and 0.2% BSA.  After washing, cells were 
incubated with FITC-conjugated mouse anti-human 
p53 monoclonal antibody anti-p53 (Ab-1, IgG2a 
Clone PAb425) (1:100) (Calbiochem, Nottingham, 
United Kingdom) or FITC-conjugated mouse 
IgG1 monoclonal isotype control antibody (BD 
Biosciences, USA) for 30 min at 4°C. After washing 
the pellet twice in wash buffer, the fluorescence of 
10,000 cells were analyzed using a FACScan flow 
cytometer (excitation 488 nm, emission pass filter 
FL-1: 530 nm) and CellQuest software (FACScan, 
BD Biosciences, USA).
Western blot analysis of p53 and p53 at Ser15
Cells were harvested by trypsinization after treatment 
and lysed for 15 min at 4°C in a lysis buffer (Tris-
HCl 50 mM pH 7.5, NaCl 150 mM, EDTA 5 mM, 
DTT 1 mM, Triton X-100 1%). The lysed cells were 
centrifuged for 30 min at 16,000 X g at 4°C, and 
the total protein content was determined by Lowry 
assay. Electrophoresis of cell lysate proteins (80 µg) 
was performed in 15% SDS-polyacrylamide gels for 
100 min at 80V and proteins were transferred onto 
nitrocellulose membranes (BioRad Laboratories, 
Marnes-la-Coquette, France) 80 min at 100V. After 
addition of a blocking solution (BSA 3%; Tween 
20 0.1%, Tris-HCl 10 mM pH 7.5, NaCl 0.1 M) for 
1 h at room temperature, the membranes were 
incubated with rabbit-polyclonal anti-human p53 
and anti-human phospho-p53 (Ser15) antibodies 
(Abcam, Paris, France) at 1:1000 and 1.500 
dilutions, respectively, or mouse anti-human beta-
actin at 1:2000 (Chemicon Int., Hampshire, U.K.). 
Subsequently, the membranes were incubated 
with 0.02 µg/ml HRP-conjugated goat anti-rabbit 
IgG (Pierce, Perbio Science, Brebières, France), 
and the proteins visualized by Super Signal West 
Pico Chemiluminescent Substrate System (Pierce, 
France). Intensity of bands was analyzed using 
BioRad Quantity One 1-D Analysis Software version 
4.2.1 (BioRad Laboratories, France).
Detection of cell surface expression of DR4 
andDR5 receptors
Cells (1x106) were seeded and treated as described 
for the sub-G0/G1 cell population. Cells were 
harvested by trypsinization, washed twice with 
ice cold PBS and incubated for 30 min at 4°C with 
anti-human-DR4 (mouse IgG1, clone HS101, 1:50) 
or anti-human-DR5 (mouse IgG1, clone HS201, 
1:50) monoclonal antibodies (Alexis Biochemicals 
Corp., Stockholm, Switzerland). For DR4 and DR5 
detection, cells were washed with ice-cold PBS 
and incubated with a secondary antibody anti-
mouse IgG1-FITC (clone STAR81F, 1:50) for 30 
min at 4°C in darkness, the excess was removed 
by two washings. Isotype control mouse IgG1-FITC 
antibody (BD Pharmingen, San Jose CA, USA) 
was used as negative control, incubated for 30 min 
at 4°C in darkness. After washing with PBS, cells 
were resuspended in PBS, and surface expression 
of 10,000 events per sample was analyzed with a 
FACScan flow cytometer and CellQuest software 
(Beckton Dickinson, USA).
Total RNA extraction and RT–PCR detection of 
DR4 and DR5 mRNA transcripts
To determine whether cell surface expression of 
DR4/DR5 at the surface level was associated with 
levels of DR4/DR5 RNA, the expression of their 
respective transcripts was quantified by RT-PCR 
and data were analyzed by a relative quantification 
method (38). Relative quantitation described the 
change in expression of the target gene (DR4 or 
DR5) relative to untreated cells (control group) 
under the same conditions for detection of cell 
surface expression of DR4/DR5. Total RNA was 
extracted using an RNeasy Mini kit (QIAGEN, VWR, 
Denmark) following manufacturer’s instructions. 
RNA was reversely transcribed using the High-
Capacity cDNA Archive Kit (Applied Biosystems, 
Foster City, CA). TaqMan gene expression assays 
were used to measure transcription levels of the 
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selected genes (DR5, Hs00366272_m1; DR4, 
Hs00269492_ml; Applied Biosystems, Foster City, 
CA). Beta-actin was applied as an endogenous 
control (catalog no. Hs99999903_m1; Applied 
Biosystems). Real time quantitative PCR was 
performed by using TaqMan Universal PCR master 
mix (Applied Biosystems) and ABI Prism 7500 
Sequence Detection System (Applied Biosystems 
Sequence detector) in triplicate wells. The data 
were analyzed by a comparative threshold cycle 
(CT) method. Values of the Δ cycle threshold (ΔCt) 
were obtained by normalizing the average Ct 
value of each treatment compared to its opposite 
endogenous control (β-actin) and then calculating 
2− DDCt for each treatment.  The statistical analyses 
were as previously described (38).
Statistical analysis
The data were presented as mean ± standard 
error (SE) from three independent experiments. 
Comparisons between groups were done by one- 
and two-way ANOVA. Comparison between treated 
and not treated with Pcy was done by two-tailed 
paired t-test. Results were considered significant 
when p<0.05. For the quantitative RT-PCR data 
Tukey’s multiple comparisons post-test was used 
to determine significance at the p<0.05 level. These 
analyses were done with the GraphPad Prism 
version 5.00 for Windows, (GraphPad Software, 
San Diego California, USA).
Results
Cell death induction by apple Pcy
Propidium iodide allowed the characterization 
of cell distribution in each phase of the cell cycle 
(G0/G1, S or G2/M) by measurement of cellular 
DNA content. Induction of cell death caused DNA 
degradation, and therefore dead cells exhibited 
a DNA content lower than 2n. These cells were 
detected by flow cytometry in the sub-G0/G1 region 
as reported previously (34). This approach permitted 
the determination of the amount of dead or dying 
cells in a population, but gave no information on 
the cell death process (39). Figure 1 shows that 
the hypodiploid population increased significantly 
(p<0.05) from 1% in the untreated control group to 
16% after 48 h exposure to apple Pcy (80 µg/ml).
Effect of Pcy on the activation of p50/p65 NF-κB 
subunits
NF-κB is a factor implicated in apoptotic cell 
death of several types of cancer cells. The above 
experiments were designed to determine if Pcy 
was able to activate the NF-κB. As shown in figure 
2A, the optical density (O.D) exhibited by active 
forms of p50 and p65 proteins in nuclear extracts of 
SW620 cells was significantly increased after Pcy 
(80 µg/ml) treatment compared to untreated cells 
for 24 h and 48 h.
Effects of Pcy on p53 expression and 
activation 
The role of p53 in Pcy-induced apoptosis was 
determined in SW620 cells, a cell line which 
expresses a mutant form of p53 (40,41). Total p53 
protein levels were measured by flow cytometry 
using a specific monoclonal antibody (PAb425) 
that recognized both mutant- and wild-type p53. 
A significantly increased expression of total p53 
protein was observed after the Pcy treatment 
(figure 2B). The effect of Pcy on the activation of 
p53 protein was tested by western blot as well. 
Activation of p53 tumor-suppressor function was 
critically dependent on the phosphorylation at 
the Ser15 residue. As shown in figure 2C, Pcy-
Figure 1. Effect of Pcy on cell death in SW620 cells. Analysis of hypodiploid cells by flow cytometry after Pcy (80 µg/ml) treatment of 
cells for 24 and 48h.  Data are presented as mean percentage ± SE of cells in the sub-G0/G1 region. The flow cytometry histograms 
are representative of three or more  experiments. Treatments were significant at p<0.05.
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increased levels of total p53 were correlated with a 
progressive increase of the phosphorylated active 
form of p53 at Ser15 by 2-fold over untreated cells.
Effect of quinazoline (QNZ) and pifithrin α (Pα) 
on Pcy-induced cell death
NF-κB and p53 transcriptional factors were 
investigated for their involvement in the Pcy-
induced cell death of SW620 cells. Flow cytometry 
was used to visualize the effects of a specific 
inhibitor of NF-κB activation (6-amino-4-(4-
phenoxyphenylethylamino) quinazoline (QNZ)) and 
a specific inhibitor of the transcriptional function of 
p53 (pifithrin α (Pα)) on the amount of hypodiploid 
cells induced by Pcy. As shown in figure 3, the Pcy-
induced cell death was reduced by 60% and by 
78% with QNZ and Pα, respectively. In contrast, a 
further increase in the amount of hypodiploid cells 
induced by Pcy was observed after a simultaneous 
inhibition of NF-κB and p53 compared to cells 
treated with Pcy/QNZ and Pcy/Pα. Taken together, 
these data suggested that NF-κB and p53 were 
partially required in the Pcy-induced cell death in 
SW620 cells.
Figure 2. (A) Effect of Pcy on the levels of p50/p65 NF-κB subunits in nuclear extracts of SW620 cells.  (B) Intracellular detection 
of total p53 protein by flow cytometry analysis. The histograms represent the percentage of cells expressing total p53 protein.  (C) 
Effect of Pcy on total and phosphor-Ser15 p53 protein in whole lysates (80 µg) of SW620 cells treated for 48h.  Data are presented 
as mean ± SE of three separate experiments. Treatments were significant at p<0.05.
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Effect of Pcy on TRAIL death receptors regulated 
by NF-κB and p53 proteins
Pcy has been shown previously to trigger 
apoptosis in SW620 cells involved the up-regulated 
expression and activation of TRAIL-DR4/-DR5 
(34,35). The current study aimed to show if Pcy-
enhanced expression of the TRAIL-death receptor 
in SW620 cells was regulated by NF-κB and p53. 
The cell surface expression of TRAIL-DR4/-DR4 
was analyzed by flow cytometry using specific 
antibodies after 48 h of treatment with Pcy single 
or combined with the inhibitors QNZ or/and Pα. As 
shown in figure 4A, the ability of Pcy to up-regulate 
cell surface expression of TRAIL-DR4 receptor 
was reduced by 59%, 46% and 80% with QNZ, Pα 
and QNZ/Pα combined treatments, respectively. 
In contrast, QNZ, with or without Pα, reduced to a 
lesser extent the amount of cells expressing at their 
cell surface TRAIL-DR5 in the presence of Pcy 
(figure 4A). These observations were confirmed by 
measuring DR4 and DR5 transcript levels by real 
time RT-PCR (figure 4B). These data suggested 
that DR4 and DR5 receptors were regulated 
differently by Pcy or Pα and QNZ. The TRAIL-DR4 
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expression may be dependent on the activation 
of NF-κB and p53  by Pcy, whereas TRAIL-DR5 
expression may be regulated by other transcription 
factors also activated by Pcy.
Discussion
The NF-κB transcription factor plays an important 
role in tumor formation and progression, in contrast 
to p53 which plays a key role in the induction of 
apoptosis (20,21). However, NF-κB may have 
divergent effects on cell survival and cell death, 
depending on the cell type and on specific activating 
signals (10-16). In the current study,  NF-κB and 
p53 transcription factors were investigated for their 
potential roles in Pcy-induced cell death of SW620 
cells.  This was accomplished by using QNZ, a 
specific inhibitor of the transcriptional activation 
of NF-κB, and by using Pα.an inhibitor of the 
transcriptional activity of p53. The results suggested 
that Pcy-induced cell death in SW620 cells required 
partly the transcriptional function of NF-κB and p53 
for the following reasons: (i) Pcy increased the 
levels of active NF-κB p50/p65 nuclear subunits, 
(ii) Pcy up-regulated the expression of p53 and its 
activated/phosphorylated form, and (iii) the type 
of cell death significantly inhibited by QNZ and Pα 
was apoptosis by a Pcy-dependent activation of 
TRAIL-DR4/-DR5 death receptors.
These results suggested that Pcy can induce an 
apoptosis dependent on NF-κB- and- p53, because 
Pcy combined with QNZ or Pα reduced significantly 
the pro-apoptotic effects of Pcy. However, the 
simultaneous inactivation of NF-κB and p53 in 
the presence of Pcy was less effective in reducing 
Figure 3. Effects of 6-amino-4-quinazoline (QNZ) and pifithrin α 
(Pα) on Pcy-induced cell death. Columns not sharing the same 
superscript letter differ significantly: a≠b≠c≠d≠e, p<0.05.
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the amount of apoptotic cells. These observations 
suggested that Pcy was also able to trigger 
apoptosis in SW620 cells by activating mechanisms 
independently of NF-κB and p53 that not involve 
regulation of pro-apoptotic genes such as TRAIL-
DR4/DR5. For example, an apoptotic mechanism 
that may be independent of NF-κB and p53 is the 
Pcy-triggered ROS production.  This mechanism is 
related to the Pcy-mediated activation of polyamine 
catabolism favoring mitochondrial dysfunction 
(34,35).
In a previous study, Pcy was found to up-regulate 
the expression of TRAIL-DR4/-DR5 receptors in 
SW620 cells, leading to the activation of TRAIL-
death receptor mediated apoptosis (34,35). 
Because both NF-κB and p53 were involved in 
apoptosis, the additional role of a Pcy-induced 
activation of NF-κB and p53 was investigated for 
its necessity in the activation of TRAIL-DR4/-DR5 
death receptors of SW620 cells. The significant 
reduction of the Pcy-induced activation of DR4/DR5 
in presence of QNZ or Pα suggested that activation 
of NF-κB or p53 was required in this process. These 
events may be associated with the Pcy-increased 
levels of active NF-κB p50/p65 subunits in nuclear 
extracts of SW620 cells, since the p65 subunit can 
induce the expression of TRAIL-DR4/-DR5 death 
receptors (12,17,42). Furthermore, the inhibition 
of p65 activation has been shown to abolish the 
expression of TRAIL-death receptors induced by 
retinoid-related molecules in human prostate and 
breast carcinoma cells (17,43).
The potentiation of Pcy-triggered apoptosis in 
SW620 cells by the polyamine oxidase inhibitor, 
MDL, has been reported to involve a depletion of 
the intracellular polyamine pool.  This depletion 
leads to an activation of the extrinsic apoptotic 
pathway by  up-regulating TRAIL-death receptor 
expression (34). These events may be associated 
to the increased basal level of NF-κB proteins and 
induced NF-κB nuclear translocation [, and activated 
its sequence specific DNA binding as] observed in 
breast cancer MCF-7 cell line (44) and intestinal 
IEC-6 cells that were depleted in polyamines (45).
The current study showed that Pcy significantly 
increased the expression of p53 and its 
phosphorylated form at Ser15. These events may 
favor the Pcy activation of TRAIL-death receptors 
in SW620 cells despite the presence of a less 
susceptible p53 mutated form  in SW620 cells 
(21). Indeed, in SW620 cells, p53 exhibits two 
point mutations: the Pro309gSer (P309S) and 
Biomédica 2010;30:577-86
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the Arg273gHis (R273H). However, the observed 
inhibition of the Pcy-induced TRAIL-DR4/-DR5 
expression by Pα suggested that p53 exhibited a 
residual transcriptional activity in SW620 cells.  This 
phenomenon has been described in other cancer 
lines through protein-protein interactions (17,21).
When Pcy-treated SW620 cells were exposed 
simultaneously to both inhibitors (QNZ and Pα), 
TRAIL-DR4 expression was significantly inhibited 
in contrast  to treatments with the inhibitors applied 
singly; these effects were not observed for TRAIL-
Figure 4. Effects of 6-amino-4-quinazoline (QNZ) and pifithrin 
α (Pα) on the expression of TRAIL-DR4/-DR5 receptors in Pcy-
treated SW620 cells. (A) Cell surface expression of DR4/DR5. 
For each cell receptor, columns not sharing the same superscript 
letter differ significantly: a≠b≠c≠d≠e and a’≠b’≠c’≠d’≠e’, *p<0.05. 
(B) Relative expression levels of DR4 and DR5 mRNA analyzed 
by real time RT-PCR after 48 h treatments with Pcy (80 µg/ml). 
Histogram represents the increased expression of treated over 
non-treated cells. Data are presented as mean ± SE of three 
separate experiments, *p<0.0001. Tukey’s multiple comparisons 
post-test was used to determine statistical differences between 
groups of treatments. For DR4 or DR5, columns not sharing 
the same superscript letter differ significantly: a≠b≠c≠d and 
a’≠b’≠c’, p<0.05. 
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DR5 and suggested that the expression of each 
TRAIL-death receptor may be regulated differently. 
The DR4 promoter region contains several AP-1 
binding sites, which are targets for c-Jun N-terminal 
kinase pathway.  These sites can be activated by 
several chemotherapeutic agents (46). In contrast 
the DR5 promoter region has  two Sp1 sites which 
are able to up-regulate DR5 transcription (47).
In conclusion, the current data have demonstrated 
that Pcy-triggered apoptosis occurred partly via the 
activation of NF-κB and p53 transcription factors 
that are directly involved in the upregulation of 
TRAIL-DR4/-DR5 death receptors. In addition, the 
DR4 and DR5 receptors appeared to be regulated 
differently and that the ratio between DR4 and DR5 
expression may play an important role in the control 
of TRAIL-death receptor mediated apoptosis.
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